Shuttle Pharmaceuticals is expected to report zero revenue and a net loss for the second quarter of 2026, with shares currently trading at $3.21, slightly above the algorithmic price target of $3.13. The primary story for this report is the company’s recent Nasdaq noncompliance notice and the resulting delay of its Q2 2026 financial results.
This administrative delay is linked to a planned merger with United Dogecoin Inc, a deal that has fundamentally altered the company’s operational focus and spending patterns. Investors are specifically monitoring research and development expenses, which preliminary disclosures indicate fell 90% year-over-year to $0.1 million. The market remains wary of delisting risks as management attempts to finalize the merger and clarify its clinical development roadmap.